These drugs were selected by an independent panel of experts because they could reduce the risk of death in hospitalized patients. COVID-19 . The manufacturers of these drugs were handed over for trials.
The World Health Organisation’s Solidarity PLUS study is the world’s largest ongoing randomized potential control study COVID-19 therapy. It represents the largest worldwide cooperation between WHO member countries.
When thousands of researchers and patients are involved, it allows the experiment to evaluate multiple treatments simultaneously using the same protocols. It also helps them get solid estimates of the drug’s impact on mortality – even moderate effects.
New treatments are being added to the guidelines, while the WHO is abandoning treatments that are ineffective or that have proven to be dangerous or ineffective.
This study began in June 2021 and will run until May 2022. It will be conducted in more than 600 hospitals in 52 countries.
“Finding more effective and more readily available medicines COVID-19 the need for patients remains critical, and the WHO is proud to lead this global work, ”said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General.
The three drugs are:
Artesunate is produced by Ipca and treats malaria. It is derived from the herb Artemisia annua. Artesunate is a derivative of Artemisinin that is considered very safe because it has been used to treat malaria for over 30 years. Artemisia annua, commonly known as Sweet Wormwood, is a plant that occurs in Asia and parts of North America. The standard dose used to treat malaria is given intravenously over seven days and its anti-inflammatory properties are assessed.
Imatinib is produced by Novartis and is a treatment for cancer. It is an oral drug, and early experimental data suggest it may “reverse pulmonary bleeding in the lungs.” It is given orally for 14 days daily.
Infliximab is produced by Johnson and Johnson and treats diseases related to the immune system. It is a TNF-alpha inhibitor, a chimeric monoclonal antibody that recognizes human TNF-alpha. These types of anti-TNF drugs have been in use for over 20 years. They have been shown to limit efficacy and safety to widespread inflammation, including in the elderly, who are the most clinically vulnerable. COVID-19 . The standard dose given to patients with Crohn’s disease is given intravenously.